269 related articles for article (PubMed ID: 33709786)
1. Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Thota S; Oganesian A; Azab M; Griffiths EA
Future Oncol; 2021 Jun; 17(16):2077-2087. PubMed ID: 33709786
[TBL] [Abstract][Full Text] [Related]
2. Decitabine/Cedazuridine: First Approval.
Dhillon S
Drugs; 2020 Sep; 80(13):1373-1378. PubMed ID: 32860582
[TBL] [Abstract][Full Text] [Related]
3. Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.
Patel AA; Cahill K; Saygin C; Odenike O
Blood Adv; 2021 Apr; 5(8):2264-2271. PubMed ID: 33904891
[TBL] [Abstract][Full Text] [Related]
4. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
Garcia-Manero G; Griffiths EA; Steensma DP; Roboz GJ; Wells R; McCloskey J; Odenike O; DeZern AE; Yee K; Busque L; O'Connell C; Michaelis LC; Brandwein J; Kantarjian H; Oganesian A; Azab M; Savona MR
Blood; 2020 Aug; 136(6):674-683. PubMed ID: 32285126
[TBL] [Abstract][Full Text] [Related]
5. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
Savona MR; Odenike O; Amrein PC; Steensma DP; DeZern AE; Michaelis LC; Faderl S; Harb W; Kantarjian H; Lowder J; Oganesian A; Azab M; Garcia-Manero G
Lancet Haematol; 2019 Apr; 6(4):e194-e203. PubMed ID: 30926081
[TBL] [Abstract][Full Text] [Related]
6. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Garcia-Manero G; McCloskey J; Griffiths EA; Yee KWL; Zeidan AM; Al-Kali A; Deeg HJ; Patel PA; Sabloff M; Keating MM; Zhu N; Gabrail NY; Fazal S; Maly J; Odenike O; Kantarjian H; DeZern AE; O'Connell CL; Roboz GJ; Busque L; Buckstein R; Amin H; Randhawa J; Leber B; Shastri A; Dao KH; Oganesian A; Hao Y; Keer HN; Azab M; Savona MR
Lancet Haematol; 2024 Jan; 11(1):e15-e26. PubMed ID: 38135371
[TBL] [Abstract][Full Text] [Related]
7. Novel agents for myelodysplastic syndromes.
Xu K; Hansen E
J Oncol Pharm Pract; 2021 Dec; 27(8):1982-1992. PubMed ID: 34558354
[TBL] [Abstract][Full Text] [Related]
8. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
Bataller A; Montalban-Bravo G; Bazinet A; Alvarado Y; Chien K; Venugopal S; Ishizawa J; Hammond D; Swaminathan M; Sasaki K; Issa GC; Short NJ; Masarova L; Daver NG; Kadia TM; Colla S; Qiao W; Huang X; Kanagal-Shamanna R; Hendrickson S; Ravandi F; Jabbour E; Kantarjian H; Garcia-Manero G
Lancet Haematol; 2024 Mar; 11(3):e186-e195. PubMed ID: 38316133
[TBL] [Abstract][Full Text] [Related]
9. FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes.
Kim N; Norsworthy KJ; Subramaniam S; Chen H; Manning ML; Kitabi E; Earp J; Ehrlich LA; Okusanya OO; Vallejo J; Gehrke BJ; de Claro RA; Pazdur R
Clin Cancer Res; 2022 Aug; 28(16):3411-3416. PubMed ID: 35435961
[TBL] [Abstract][Full Text] [Related]
10. The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes.
Kipp D; H Wei A
Future Oncol; 2021 Jul; 17(20):2563-2571. PubMed ID: 33769069
[TBL] [Abstract][Full Text] [Related]
11. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.
Haumschild R; Kennerly-Shah J; Barbarotta L; Zeidan AM
J Oncol Pharm Pract; 2024 Jun; 30(4):721-736. PubMed ID: 38509812
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia.
Molina JC; Asare JM; Tuschong L; West RR; Calvo KR; Persky R; Boyce AM; Hammoud DA; Holland SM; Hickstein D; Shah NN
Pediatr Blood Cancer; 2021 Mar; 68(3):e28865. PubMed ID: 33369023
[TBL] [Abstract][Full Text] [Related]
13. The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era.
Schiffer M; Zhao J; Johnson A; Lee J; Bewersdorf JP; Zeidan AM
Expert Rev Anticancer Ther; 2021 Sep; 21(9):989-1002. PubMed ID: 33853476
[TBL] [Abstract][Full Text] [Related]
14. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
15. Decitabine plus cedazuridine and venetoclax: the promise of an all-oral therapy for patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Assouline S
Lancet Haematol; 2024 Mar; 11(3):e170-e171. PubMed ID: 38316134
[No Abstract] [Full Text] [Related]
16. New landscapes in the management of myelodysplastic syndromes and chronic myelomonocytic leukemia: oral decitabine.
Niscola P; Mazzone C; Molica M; de Fabritiis P
Future Oncol; 2021 Jun; 17(16):1973-1975. PubMed ID: 33878941
[No Abstract] [Full Text] [Related]
17. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.
Yi JH; Huh J; Kim HJ; Kim SH; Kim SH; Kim KH; Do YR; Mun YC; Kim H; Kim MK; Kim HJ; Kim T; Kim DD
Ann Hematol; 2013 Apr; 92(4):459-69. PubMed ID: 23262795
[TBL] [Abstract][Full Text] [Related]
19. Oral hypomethylating agents: beyond convenience in MDS.
Griffiths EA
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):439-447. PubMed ID: 34889435
[TBL] [Abstract][Full Text] [Related]
20. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
Patnaik MM; Lasho T
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
